ProMune: Clinical Trials

23 trials of ProMune, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed, 5 terminated, 2 withdrawn, 1 unknown. 23 Phase 2, 11 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 223Completed 15, Terminated 5, Withdrawn 2, Unknown 1
Phase 111Completed 7, Terminated 2, Unknown 1, Withdrawn 1

Follow ProMune: new trials by email Literature Review of ProMune trials Research Report on ProMune

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess Safety, Immunogenicity and Parasite Growth Inhibition of an Asexual Blood Stage Vaccine for P. Falciparum Malaria
AMA1-C1/Alhydrogel® + CPG 7909 - Malaria
Phase 1 / Phase 2CompletedUniversity of Oxford82010-01-012015-05-28
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
CpG-MCL vaccine, PF-3512676, Vaccine-primed T-cells - Lymphoma, Mantle-Cell
Phase 2CompletedRonald Levy592009-08-012020-01-13
Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Trastuzumab, PF03512676, Correlative Studies - Breast Cancer
Phase 2TerminatedBhuvaneswari Ramaswamy62009-02-012016-01-14
A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas
PF-3512676, Local radiotherapy - Lymphoma, Non-Hodgkin, Lymphoma
Phase 2CompletedRonald Levy302009-01-012017-03-14
Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected Adults
Pneumococcal vaccines + CPG 7909, Pneumococcal vaccines - HIV Infections
Phase 1 / Phase 2CompletedUniversity of Aarhus972008-01-012009-01-21
A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.
docetaxel, PF-3512676 - Breast Neoplasms
Phase 2WithdrawnPfizer2007-08-012015-05-04
PhaseⅠ/Ⅱ Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer
URLC10-177, TTK-567, CpG-7909 - Esophageal Cancer
Phase 1 / Phase 2UnknownWakayama Medical University292006-11-012010-09-09
Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer
pemetrexed, pemetrexed + PF-3512676 - Carcinoma, Non-Small Cell Lung
Phase 2TerminatedPfizer362006-09-012009-09-28
Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer
PF-3512676 + Erlotinib, Erlotinib - Carcinoma, Non-Small-Cell Lung
Phase 2CompletedPfizer432006-08-012010-12-23
Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC
paclitaxel + carboplatin + bevacizumab, carboplatin + paclitaxel + bevacizumab + PF-3512676 - Carcinoma, Non-Small-Cell Lung
Phase 2TerminatedPfizer232005-12-012009-09-28
Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.
CPG 7909 - Mycosis Fungoides
Phase 1 / Phase 2WithdrawnStanford University2005-03-012016-12-01
Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma
MAGE-3.A1 peptide and CpG 7909 - Malignant Melanoma
Phase 1 / Phase 2TerminatedLudwig Institute for Cancer Research12005-01-122022-10-07
Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma
8 HLA-A2-restricted peptides and Montanide ISA51, 8 HLA-A2-restricted peptides and CpG 7909 - Malignant Melanoma
Phase 1 / Phase 2TerminatedLudwig Institute for Cancer Research232005-01-012022-10-10
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Agatolimod Sodium, Indium In-111 Ibritumomab Tiuxetan, Laboratory Biomarker Analysis - Adult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Phase 1 / Phase 2CompletedMayo Clinic382004-10-012016-02-04
CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
CPG 7909 - Non-Hodgkin Lymphoma, Mycosis Fungoides
Phase 1 / Phase 2CompletedRonald Levy302004-07-012014-08-01
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size
Phase 2CompletedUniversity of Southern California422004-05-012014-05-22
CPG 7909 Injection in Melanoma
CPG 7909 Injection, dacarbazine, Chemotherapy - Carcinoma, Melanoma
Phase 2CompletedPfizer1842003-12-012009-02-10
CPG 7909 Injection in Non-Small Cell Lung Cancer
CPG 7909, Chemotherapy - Carcinoma, Non-Small Cell Lung
Phase 2CompletedPfizer1162003-05-012009-02-10
CPG 7909 in Patients With Cutaneous T-Cell Lymphoma
PF-3512676 - Lymphoma, T-Cell, Cutaneous
Phase 1 / Phase 2CompletedPfizer422003-01-012009-02-12
CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer
0.04 mg/kg CpG 7909, Herceptin®, 0.08 mg/kg CpG 7909 - Carcinoma, Breast
Phase 2CompletedPfizer162002-09-012009-03-12

Showing 20 of 23. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (5)  ·  Melanoma (5)  ·  Breast Neoplasms (4)  ·  Lymphoma (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Carcinoma (2)  ·  Carcinoma, Renal Cell (2)  ·  Lymphoma, Mantle-Cell (2)  ·  Mycosis Fungoides (2)  ·  Breast Neoplasms, Male (1)  ·  Esophageal Neoplasms (1)  ·  HIV Infections (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lung Neoplasms (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)

Sponsors

Pfizer (11)  ·  Ronald Levy (3)  ·  Ludwig Institute for Cancer Research (2)  ·  Bhuvaneswari Ramaswamy (1)  ·  Mayo Clinic (1)  ·  Stanford University (1)  ·  University of Aarhus (1)  ·  University of Oxford (1)  ·  University of Southern California (1)  ·  Wakayama Medical University (1)

Countries

United States (13)  ·  Germany (3)  ·  Belgium (2)  ·  Canada (1)  ·  Denmark (1)  ·  Italy (1)  ·  Japan (1)  ·  United Kingdom (1)

Top investigators

Ronald Levy (3)  ·  Adrian VS Hill, D.Phil, FRCP (1)  ·  Bhuvaneswari Ramaswamy, MD (1)  ·  Harold Burstein, M.D., Ph.D. (1)  ·  Jeffrey Weber (1)  ·  Lars Ostergaard, MD,PhD,DmSC (1)  ·  Nicolas VanBaren, MD (1)  ·  Nicolas van Baren, MD (1)  ·  Ole Sogaard, MD (1)  ·  Ronald Levy, MD (1)  ·  Thierry Boon, PhD (1)  ·  Thomas Witzig (1)

Results publications

PMID 22045986, PMID 20504165, PMID 20697067, PMID 20874827, PMID 20888065, PMID 21799809, PMID 22854665, PMID 23792641, PMID 32558897, PMID 32632956

NIH funding

P30CA015083 (1)